A new report published by Irish biotechnology company Shire has shown that rare disease patients in England, UK, have to wait an average of two years for life-changing treatments to be funded on the National Health Service (NHS).

The finding also highlights the fact that more than half (52%) of the life-changing medications for rare diseases approved over the past 15 years in England are not funded for routine use.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Titled ‘Equity and Access: Making the UK a Rare Disease Leader’, the report has been funded and initiated by Shire and highlights the findings, along with a recommendation for collaboration with the government, to develop new, tailored process to examine rare disease medicines.

Based on the analysis of the availability of rare disease medicines across five countries in Europe, the report reveals that patient access in England falls behind that in France, Germany, Spain and Italy.

"We need to shine a light on these issues and put together an action plan to ensure that people living with rare diseases in England have fair and equal access to the treatment they need."

The company has brought together leaders from several medical communities, policy-makers, patient advocacy and healthcare to review information analysed by UK’s Office of Health Economics (OHE).

See Also:

Shire UK and Ireland Country Cluster head and general manager Sebastian Stachowiak said: “Significant strides have been made in innovating and developing new medicines for people living with rare diseases, and yet patients in this country are still facing uncertain waits for treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We need to shine a light on these issues and put together an action plan to ensure that people living with rare diseases in England have fair and equal access to the treatment they need.”

Out of the 143 medicines approved by the European Medicines Agency (EMA), 48% (68) were funded by the NHS in England, while 93% (133) were funded in Germany and 81% (116) in France.